Pharmacological modulation of plaque instability

Lupus

Volumn 14, Issue 9, 2005, Pages 769-772

  Mezzetti, Andrea ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Centro Regionale per la Prevenzione dell'Aterosclerosi   (Italy)

Author keywords

AT1 receptor blockers; Inflammation; Plaque; Statins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CHLORTALIDONE; CYCLOOXYGENASE 2; DEXAMETHASONE; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PROSTAGLANDIN E; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; SIMVASTATIN; SYNTHETASE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE INSTABILITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATHEROSCLEROSIS; CYCLOOXYGENASE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRAMOLECULAR OXIDOREDUCTASES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS;

EID: 26244444313     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2218oa     Document Type: Review

References (30)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
5. Loftus IM, Naylor R, Goodall S et al. Increased matrix-metalloproteinase- 9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 2000; 31: 40-47.
6. Cipollone F, Prontera C, Pini B et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104: 921-927.
7. Matsumoto H, Naraba H, Murakami M et al. Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide- stimulated rat peritoneal macrophages. Biochem Biophys Res Commun 1997; 230: 110-114.
8. Mitchell J, Belvisi M, Akarasereenont P et al. Induction of cyclooxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol 1994; 113: 1008-1014.
9. Newton R, Kuitert LM, Slater DM, Adcock IM, Barnes PJ. Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci 1997; 60: 67-78.
10. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665.
11. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
12. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase in human monocytes. J Biol Chem 1990; 265: 16737-16740.
13. Herron GS, Werb Z, Dwyer K et al. Secretion of metalloproteinases by Holmes DR, Wester W, Thompson RW, Reilly JM. Prostaglandin E2 synthesis, and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997; 25: 810-815.
14. Arias-Negrete S, Kelley K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 expression in human macrophages. Biochem Biophys Res Commun 1995; 208: 582-589.
15. Burleigh ME, Babaev VR, Oates JA et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-1823.
16. Huttner JJ, Gwebu ET, Panganamala RV et al. Fatty acids and their prostaglandin derivatives: inhibitors of proliferation in aortic smooth muscle cells. Science 1977; 197: 289-291.
17. Cipollone F, Fazia M, Iezzi A et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003; 107: 1479-1485.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
19. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
20. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
21. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
22. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
23. Degraeve F, Bolla M, Blaie S et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 2001; 276: 46849-46855.
24. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105; 1605-1612.
25. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase-2 by Angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 2000; 35: 68-75.
26. Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 1995; 76: 8D-13D.
27. Cipollone F, Fazia M, Iezzi A et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-1488.
28. The HOPE Study Investigators. Effects of an Ang-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
29. Wing LMH, Reid CM, Ryan P et al. Second Australian National Blood Pressure Study. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
30. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.